Insider · CIK 0001816523
Zachary Scheiner
Files at SGP (SpyGlass Pharma, Inc.), NKTX (Nkarta, Inc.), LENZ (LENZ Therapeutics, Inc.). First filing -, latest -.
In brief
Zachary Scheiner files SEC Form 4 as director at SGP (SpyGlass Pharma, Inc.), and also at NKTX (Nkarta, Inc.), LENZ (LENZ Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Zachary Scheiner has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +22,100 | $0.00 | $0 | 22,100 | Jun 15, 2026 |
| Jun 10, 2026 | NKTX Nkarta, Inc. | AGrant or award Stock Option (right to buy)derivative | +37,000 | $0.00 | $0 | 37,000 | Jun 11, 2026 |
| Feb 5, 2026 | SGP SpyGlass Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,400 | $0.00 | $0 | 27,400 | Feb 9, 2026 |
| Jun 11, 2025 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Jun 11, 2025 |
| Jun 5, 2025 | NKTX Nkarta, Inc. | AGrant or award Stock Option (right to buy)derivative | +46,000 | $0.00 | $0 | 46,000 | Jun 9, 2025 |
Questions about Zachary Scheiner
Answered from the filings on this page, as of the latest one.
Is Zachary Scheiner buying or selling?
Zachary Scheiner has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Zachary Scheiner's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Zachary Scheiner has 0.
Where does Zachary Scheiner file Form 4?
Zachary Scheiner has filed Form 4 at SGP (SpyGlass Pharma, Inc.); NKTX (Nkarta, Inc.); LENZ (LENZ Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.